References
- Cancer [Internet]. [cited 2021 Nov 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
- Targeted therapy for cancer - NCI [Internet]. 2014 [cited 2021 Sept 15]. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies
- Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546-58. DOI: 10.1126/science.1235122
- Fiore LD, Brophy MT, Turek S, Kudesia V, Ramnath N, Shannon C, et al. The va point-of-care precision oncology program: balancing access with rapid learning in molecular cancer medicine. Biomark Cancer. 2016;8:9-16. DOI: 10.4137/BIC.S37548
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. DOI: 10.3322/caac.21492
- AACR Project GENIE Consortium. Aacr project genie: powering precision medicine through an international consortium. Cancer Discov. 2017 Aug;7(8):818-31.
- Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015 Feb 26;372(9):793-5. DOI: 10.1056/NEJMp1500523
- Miller FA, Krueger P, Christensen RJ, Ahern C, Carter RF, Kamel-Reid S. Postal survey of physicians and laboratories: Practices and perceptions of molecular oncology testing. BMC Health Services Research. 2009 Jul 30;9(1):131. DOI: 10.1186/1472-6963-9-131
- Schink JC, Trosman JR, Weldon CB, Siziopikou KP, Tsongalis GJ, Rademaker AW, et al. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. J Natl Cancer Inst. 2014 Oct;106(10):dju256. DOI: 10.1093/jnci/dju256
- Miller FA, Hayeems RZ, Bytautas JP, Bedard PL, Ernst S, Hirte H, et al. Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur J Hum Genet. 2014 Mar;22(3):391-5. DOI: 10.1038/ejhg.2013.158
- Rheinbay E. The genomic landscape of advanced cancer. Nat Cancer. 2020 Apr;1(4):372-3. DOI: 10.1038/s43018-020-0057-z
- Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 1993 Nov 25;366(6453):362-5. DOI: 10.1038/366362a0
- Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003 Mar 14;299(5613):1753-5. DOI: 10.1126/science.1080902
- El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019 Jul;69(4):305-43. DOI: 10.3322/caac.21560
- du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS. Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res. 2019 May 15;11:4297-312. DOI: 10.2147/CMAR.S151023
- Tykodi SS, Schadendorf D, Cella D, Reck M, Harrington K, Wagner S, et al. Patient-reported outcomes with nivolumab in advanced solid cancers. Cancer Treat Rev. 2018 Nov;70:75-87. DOI: 10.1016/j.ctrv.2018.08.001
- Chrzanowska NM, Kowalewski J, Lewandowska MA. Use of fluorescence in situ hybridization (Fish) in diagnosis and tailored therapies in solid tumors. Molecules. 2020 Apr 17;25(8):1864. DOI: 10.3390/molecules25081864
- Rosa FE, Santos RM, Rogatto SR, Domingues M a. C. Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas. Braz J Med Biol Res. 2013 Mar;46(3):207-16. DOI: 10.1590/1414-431X20132483
- Sáez A, Andreu FJ, Seguí MA, Baré ML, Fernández S, Dinarés C, et al. HER-2 gene amplification by chromogenic in situ hybridisation (Cish) compared with fluorescence in situ hybridisation (Fish) in breast cancer-A study of two hundred cases. Breast. 2006 Aug;15(4):519-27. DOI: 10.1016/j.breast.2005.09.008
- Broholm H, Born PW, Guterbaum D, Dyrbye H, Laursen H. Detecting chromosomal alterations at 1p and 19q by FISH and DNA fragment analysis--a comparative study in human gliomas. Clin Neuropathol. 2008;27(6):378-87. DOI: 10.5414/NPP27378
- Home - nih genetic testing registry (GTR) - ncbi [Internet]. [cited 2023 Jun 12]. Available from: https://www.ncbi.nlm.nih.gov/gtr/
- Wideroff L, Freedman AN, Olson L, Klabunde CN, Davis W, Srinath KP, et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):295-303.
- Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008 Feb;129(2):263-73. DOI: 10.1309/99AE032R9FM8WND1
- Combining highly multiplexed pcr with semiconductor-based sequencing for rapid cancer genotyping. The Journal of Molecular Diagnostics. 2013 Mar 1;15(2):171-6. DOI: 10.1016/j. jmoldx.2012.09.003
- Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians’ attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014 May 1;32(13):1317-23. DOI: 10.1200/JCO.2013.52.4298
- Gray SW, Park ER, Najita J, Martins Y, Traeger L, Bair E, et al. Oncologists’ and cancer patients’ views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med. 2016 Oct;18(10):1011-9. DOI: 10.1038/gim.2015.207
- Johnson LM, Valdez JM, Quinn EA, Sykes AD, McGee RB, Nuccio R, et al. Integrating next-generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics. Cancer. 2017 Jun 15;123(12):2352-9. DOI: 10.1002/cncr.30581
- Gene expression profiling tests for early-stage invasive breast cancer: a health technology assessment. Ont Health Technol Assess Ser. 2020 Mar 6;20(10):1-234.
- Ananda G, Mockus S, Lundquist M, Spotlow V, Simons A, Mitchell T, et al. Development and validation of the JAX Cancer Treatment ProfileTM for detection of clinically actionable mutations in solid tumors. Exp Mol Pathol. 2015 Feb;98(1):106-12. DOI: 10.1016/j. yexmp.2014.12.009
- Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1757-65. DOI: 10.1056/NEJMoa0804385
- Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RVL. Technological advancements in cancer diagnostics: Improvements and limitations. Cancer Rep (Hoboken). 2023 Jan 6;6(2):e1764. DOI: 10.1002/cnr2.1764
- Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013 Nov;31(11):1023-31. DOI: 10.1038/nbt.2696
- Cottrell CE, Al-Kateb H, Bredemeyer AJ, Duncavage EJ, Spencer DH, Abel HJ, et al. Validation of a next-generation sequencing assay for clinical molecular oncology. J Mol Diagn. 2014 Jan;16(1):89-105.
- Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014 Feb;27(2):314-27. DOI: 10.1038/modpathol.2013.122
- Tsongalis GJ, Peterson JD, de Abreu FB, Tunkey CD, Gallagher TL, Strausbaugh LD, et al. Routine use of the Ion Torrent AmpliSeqTM Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med. 2014 May;52(5):707-14. DOI: 10.1515/cclm-2013-0883
- Gottlieb B, Beitel LK, Trifiro M. Changing genetic paradigms: creating next-generation genetic databases as tools to understand the emerging complexities of genotype/phenotype relationships. Human Genomics. 2014 May 22;8(1):9. DOI: 10.1186/1479-7364-8-9
- Hélias-Rodzewicz Z, Funck-Brentano E, Baudoux L, Jung CK, Zimmermann U, Marin C, et al. Variations of BRAF mutant allele percentage in melanomas. BMC Cancer. 2015 Jul 4;15:497. DOI: 10.1186/s12885-015-1515-3
- Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003 Jul 15;63(14):3883-5.
- Orlova KV, Ledin EV, Zhukova NV, Orlova RV, Karabina EV, Volkonskiy MV, et al. Real-world experience with targeted therapy in BRAF mutant advanced melanoma patients: results from a multicenter retrospective observational study advanced melanoma in russia(Experience)(Admire). Cancers (Basel). 2021 May 21;13(11):2529. DOI: 10.3390/cancers13112529
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun 27;417(6892):949-54.
- Genomic classification of cutaneous melanoma. Cell. 2015 Jun 18;161(7):1681-96.
- Gray PN, Dunlop CLM, Elliott AM. Not all next generation sequencing diagnostics are created equal: understanding the nuances of solid tumor assay design for somatic mutation detection. Cancers (Basel). 2015 Jul 17;7(3):1313-32. DOI: 10.3390/cancers7030837
- Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009 Aug 18;101(4):715-21. DOI: 10.1038/sj.bjc.6605177
- Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997 May 30;272(22):14459-64. DOI: 10.1074/jbc.272.22.14459
- Brock EJ, Ji K, Reiners JJ, Mattingly RR. How to target activated ras proteins: direct inhibition vs. Induced mislocalization. Mini Rev Med Chem. 2016;16(5):358-69. DOI: 10.2174/13895575156661 51001154002
- Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, et al. Standardized decision support in next generation sequencing reports of somatic cancer variants. Mol Oncol. 2014 Jul;8(5):859-73. DOI: 10.1016/j.molonc.2014.03.021
- Holleman MS, van Tinteren H, Groen HJ, Al MJ, Uyl-de Groot CA. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Onco Targets Ther. 2019;12:1413-21. DOI: 10.2147/OTT.S189438
- Schulze AB, Evers G, Kerkhoff A, Mohr M, Schliemann C, Berdel WE, et al. Future options of molecular-targeted therapy in small cell lung cancer. Cancers (Basel). 2019 May 17;11(5):690. DOI: 10.3390/cancers11050690
- Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019 Dec 17;4:61. DOI: 10.1038/s41392-019-0099-9
- Martins M, Mansinho A, Cruz-Duarte R, Martins SL, Costa L. Anti-EGFR therapy to treat metastatic colorectal cancer: not for all. In: Jordan P, editor. Targeted Therapy of Colorectal Cancer Subtypes [Internet]. Cham: Springer International Publishing; 2018. p. 113-31. DOI: 10.1007/978-3-030-02771-1_8
- Spagnuolo A, Maione P, Gridelli C. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. Expert Opinion on Emerging Drugs. 2018 Jul 3;23(3):231-41. DOI: 10.1080/14728214.2018.1527902
- Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, et al. Advances in her2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clinical Cancer Research. 2019 Apr 1;25(7):2033-41. DOI: 10.1158/1078-0432.CCR-18-2275
- Song LJ, Ge HJ, Shi XQ, Shen WW. Prognostic and predictive values of the KIT11-mutated grading system in patients with gastrointestinal stromal tumors: a retrospective study. Human Pathology. 2021 Apr;110:31-42. DOI: 10.1016/j. humpath.2021.01.001
- Shen Y, Ma X, Wang M, Zhuang C, Ni B, Tu L, et al. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors. Cancer Med. 2020 Jul 22;9(18):6485-96. DOI: 10.1002/cam4.3212
- Martín-Algarra S, Fernández-Figueras MT, López-Martín JA, Santos-Briz A, Arance A, Lozano MD, et al. Guidelines for biomarker testing in metastatic melanoma: a national consensus of the spanish society of pathology and the spanish society of medical oncology. Clin Transl Oncol. 2014 Apr;16(4):362-73. DOI: 10.1007/s12094-013-1090-5
- Liu X, Wu C, Li C, Boerwinkle E. Dbnsfp v3. 0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site snvs. Hum Mutat. 2016 Mar;37(3):235-41. DOI: 10.1002/humu.22932
- Liu X, Li C, Mou C, Dong Y, Tu Y. Dbnsfp v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site snvs. Genome Medicine. 2020 Dec 2;12(1):103. DOI: 10.1186/s13073-020-00803-9
- Madhavan S, Subramaniam S, Brown TD, Chen JL. Art and challenges of precision medicine: interpreting and integrating genomic data into clinical practice. Am Soc Clin Oncol Educ Book. 2018 May 23;38:546-53. DOI: 10.1200/EDBK_200759
- Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. npj Precis Onc. 2021 Jul 20;5(1):69. DOI: 10.1038/s41698-021-00206-y
- Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. Ha P, editor. PLoS ONE. 2020 Sep 25;15(9):e0237802. DOI: 10.1371/journal. pone.0237802
- Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, et al. CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol. 2018 Dec 12;8:608. DOI: 10.3389/fonc.2018.00608
- Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019 Mar;21(3):25. DOI: 10.1007/s11912-019-0769-3
- Li CJ, Tzeng YDT, Chiu YH, Lin HY, Hou MF, Chu PY. Pathogenesis and potential therapeutic targets for triple-negative breast cancer. Cancers. 2021 Jun 14;13(12):2978. DOI: 10.3390/cancers13122978
- Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ, Campbell FM, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. JCO. 2011 Apr 20;29(12):1531-8. DOI: 10.1200/JCO.2010.30.3677
- Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3. 2022, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022 May;20(5):497-530.
- Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the moscato 01 trial. Cancer Discovery. 2017 Jun 1;7(6):586-95. DOI: 10.1158/2159-8290.CD-16-1396
- Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 May;25(5):751-8. DOI: 10.1038/s41591-019-0424-4
- Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28;363(18):1693-703. DOI: 10.1056/NEJMoa1006448
- Non-small cell lung carcinoma - my cancer genome [Internet]. [cited 2021 Oct 22]. Available from: https://www.mycancergenome.org/content/disease/non-small-cell-lung-carcinoma/
- Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CM, Ausems MGEM, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015 Feb 1;136(3):668-77. DOI: 10.1002/ijc.29032
- Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Modern Pathology. 2011 Jul;24(7):924-31. DOI: 10.1038/modpathol.2011.54
- Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Research. 2010 Jul 1;70(13):5199-202. DOI: 10.1158/0008-5472.CAN-10-0918
- Jain VK, Turner NC. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res. 2012 Jun;14(3):208. DOI: 10.1186/bcr3139
- Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Research. 2010 Mar 1;70(5):2085-94. DOI: 10.1158/0008-5472. CAN-09-3746
- Heiskanen M, Kononen J, Bärlund M, Torhorst J, Sauter G, Kallioniemi A, et al. Cgh, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Analytical Cellular Pathology. 2001;22(4):229-34. DOI: 10.1155/2001/981218
- Peixoto A, Pinto P, Guerra J, Pinheiro M, Santos C, Pinto C, et al. Tumor testing for somatic and germline BRCA1/BRCA2 variants in ovarian cancer patients in the context of strong founder effects. Front Oncol. 2020 Jul 31;10:1318. DOI: 10.3389/fonc.2020.01318
- The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 30;474(7353):609-15. DOI: 10.1038/nature10166
- Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019 Dec 19;381(25):2416-28. DOI: 10.1056/NEJMoa1911361
- Peixoto A, Santos C, Pinto P, Pinheiro M, Rocha P, Pinto C, et al. The role of targeted BRCA1 / BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry. Clin Genet. 2015 Jul;88(1):41-8. DOI: 10.1111/cge.12441
- The Cancer Genome Atlas Research Network, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67-73. DOI: 10.1038/nature12113
- León-Castillo A, Britton H, McConechy MK, McAlpine JN, Nout R, Kommoss S, et al. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol. 2020 Mar;250(3):323-35. DOI: 10.1002/path.5372
- Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, et al. BRAF mutants evade erk-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell. 2015 Sep;28(3):370-83. DOI: 10.1016/j.ccell.2015.08.001
- Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017 Aug;548(7666):234-8. DOI: 10.1038/nature23291
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42. DOI: 10.1056/NEJMoa032691
- Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019 Dec;30(12):1884-901. DOI: 10.1093/annonc/mdz411
- Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2. 2021, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2021 Mar 2;19(3):329-59. DOI: 10.6004/jnccn.2021.0012
- Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010 Mar 16;10:101. DOI: 10.1186/1471-2407-10-101
- Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, et al. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol. 2015 Sep;7(5):252-62. DOI: 10.1177/1758834015591952
- Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature. 1998 Sep;395(6697):89-93. DOI: 10.1038/25779
- Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumour. Nature. 1993 Apr;362(6422):749-51. DOI: 10.1038/362749a0
- Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the victor trial. JCO. 2010 Oct 20;28(30):4575-80. DOI: 10.1200/JCO.2010.29.6244
- Colorectal carcinoma - my cancer genome [Internet]. [cited 2021 Sept 21]. Available from: https://www.mycancergenome.org/content/disease/colorectal-carcinoma/
- Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the american society for clinical pathology, college of american pathologists, association for molecular pathology, and the american society of clinical oncology. JCO. 2017 May 1;35(13):1453-86. DOI: 10.1200/JCO.2016.71.9807
- Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, et al. Vemurafenib for the treatment of locally advanced or metastatic BRAF v600 mutation-positive malignant melanoma: a nice single technology appraisal. PharmacoEconomics. 2013 Dec;31(12):1121-9. DOI: 10.1007/s40273-013-0094-x
- Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2021 May 1;19(5):541-65. DOI: 10.6004/jnccn.2021.0022
- Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, et al. The growing role of precision and personalized medicine for cancer treatment. Technology. 2018 Sep;06(03n04):79-100. DOI: 10.1142/S2339547818300020
- Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, et al. Personalized medicine: recent progress in cancer therapy. Cancers. 2020 Apr 19;12(4):1009. DOI: 10.3390/cancers12041009
- McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015 Jan;27(1):15-26. DOI: 10.1016/j.ccell.2014.12.001
- Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O’Brien SA, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020 Apr;181(2):442-459.e29. DOI: 10.1016/j.cell.2020.03.048
- Le Tourneau C, Belin L, Paoletti X, Bièche I, Kamal M. Precision medicine: lessons learned from the SHIVA trial - Authors’ reply. Lancet Oncol. 2015 Dec;16(16):e581-582. DOI: 10.1016/S1470-2045(15)00455-6
- Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015 Oct;16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6
- Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731-9. DOI: 10.1056/NEJMoa1714448
- Märkl B, Hirschbühl K, Dhillon C. NTRK-Fusions - A new kid on the block. Pathology - Research and Practice. 2019 Oct;215(10):152572. DOI: 10.1016/j.prp.2019.152572
- Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Feb;15(2):95-111. DOI: 10.1038/nrclinonc.2017.157
- Kalyan A, Kircher S, Shah H, Mulcahy M, Benson A. Updates on immunotherapy for colorectal cancer. J Gastrointest Oncol. 2018 Feb;9(1):160-9. DOI: 10.21037/jgo.2018.01.17
- Larotrectinib Sulfate (Vitraki) prescribing information. Revised November 2018. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210861
- Erdafitinib (Balversa) prescribing information. Revised April 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf
- Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR -mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-25. DOI: 10.1056/NEJMoa1713137
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PDL1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-33. DOI: 10.1056/NEJMoa1606774
- Pilié PG, Gay CM, Byers LA, O’Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA -mutant cancers. Clinical Cancer Research. 2019 Jul 1;25(13):3759-71. DOI: 10.1158/1078-0432. CCR-18-0968
- Lavin Y, Kobayashi S, Leader A, Amir EAD, Elefant N, Bigenwald C, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017 May 4;169(4):750-765.e17. DOI: 10.1016/j.cell.2017.04.014
- Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005 Apr;434(7035):917-21. DOI: 10.1038/nature03445
- Melanoma - my cancer genome [Internet]. [cited 2021 July 22]. Available from: https://www.mycancergenome.org/content/disease/melanoma/
- Yofe I, Dahan R, Amit I. Single-cell genomic approaches for developing the next generation of immunotherapies. Nat Med. 2020 Feb;26(2):171-7. DOI: 10.1038/s41591-019-0736-4